EDITIORIAL

779 Immunotherapy of gastric cancer: Present status and future perspectives
Triantafillidis JK, Konstadoulakis MM, Papalois AE

794 Immune signature of small bowel adenocarcinoma and the role of tumor microenvironment
Christodoulidis G, Kouliou MN, Koumarelas KE

799 Management of autoimmune hepatitis induced by hepatitis delta virus
Gigi E, Lagopoulos V, Liakos A

806 Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era
Zhong JH

OPINION REVIEW

811 Nonsteroidal anti-inflammatory drugs before endoscopic ultrasound guided tissue acquisition to reduce the incidence of post procedural pancreatitis

REVIEWS

817 Autoimmune pancreatitis: Cornerstones and future perspectives
Gallo C, Dispinzieri G, Zucchini N, Invernizzi P, Massironi S

MINIREVIEWS

833 Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
Qiu XX, Cheng SL, Liu YH, Li Y, Zhang R, Li NN, Li Z

ORIGINAL ARTICLE

Retrospective Study

843 Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus
Wu HX, Ding XY, Xu YW, Yu MH, Li XM, Deng N, Chen JL

855 Immunoglobulin G-mediated food intolerance and metabolic syndrome influence the occurrence of reflux esophagitis in Helicobacter pylori-infected patients

863 Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor
Deng GM, Song HB, Du ZZ, Xue YW, Song HJ, Li YZ
## Contents

<table>
<thead>
<tr>
<th>Type</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Observational Study</strong></td>
<td>Mitochondrial dysfunction affects hepatic immune and metabolic remodeling in patients with hepatitis B virus-related acute-on-chronic liver failure</td>
<td>881</td>
</tr>
<tr>
<td></td>
<td>Zhang Y, Tian XL, Li JQ, Wu DS, Li Q, Chen B</td>
<td></td>
</tr>
<tr>
<td><strong>Basic Study</strong></td>
<td>Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma</td>
<td>901</td>
</tr>
<tr>
<td></td>
<td>Wang YY, Shen MM, Gao J</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lipid metabolism-related long noncoding RNA RP11-817I4.1 promotes fatty acid synthesis and tumor progression in hepatocellular carcinoma</td>
<td>919</td>
</tr>
<tr>
<td><strong>SYSTEMATIC REVIEWS</strong></td>
<td>Quality of life after pancreatic surgery</td>
<td>943</td>
</tr>
<tr>
<td></td>
<td>Li SZ, Zhen TT, Wu Y, Wang M, Qin TT, Zhang H, Qin RY</td>
<td></td>
</tr>
<tr>
<td><strong>META-ANALYSIS</strong></td>
<td>Prevalence and clinical impact of sarcopenia in liver transplant recipients: A meta-analysis</td>
<td>956</td>
</tr>
<tr>
<td></td>
<td>Jiang MJ, Wu MC, Duan ZH, Wu J, Xu XT, Li J, Meng QH</td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTOMETRICS</strong></td>
<td>Bibliometrics analysis based on the Web of Science: Current trends and perspective of gastric organoid during 2010-2023</td>
<td>969</td>
</tr>
<tr>
<td><strong>CASE REPORT</strong></td>
<td>Cronkhite-Canada syndrome with esophagus involvement and six-year follow-up: A case report</td>
<td>984</td>
</tr>
<tr>
<td></td>
<td>Tang YC</td>
<td></td>
</tr>
<tr>
<td><strong>LETTER TO THE EDITOR</strong></td>
<td>Monitoring of hepatocellular carcinoma</td>
<td>991</td>
</tr>
<tr>
<td></td>
<td>Akkari I, Jaziri H</td>
<td></td>
</tr>
</tbody>
</table>
## ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Neal Shahidi, MD, FRCP, PhD, Assistant Professor, Department of Medicine, Division of Gastroenterology, St Paul’s Hospital, Vancouver V6Z 2K5, British Columbia, Canada. nshahidi@providencehealth.bc.ca

## AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

## INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.3.

## RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yu-Xi Chen; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

### NAME OF JOURNAL

*World Journal of Gastroenterology*

### ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

### LAUNCH DATE

October 1, 1995

### FREQUENCY

Weekly

### EDITORS-IN-CHIEF

Andrzej S Tarnawski

### EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

### EDITORIAL BOARD MEMBERS


### PUBLICATION DATE

February 28, 2024

### COPYRIGHT

© 2024 Baishideng Publishing Group Inc

### PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

### INSTRUCTIONS TO AUTHORS

[https://www.wjgnet.com/bpg/gerinfo/204](https://www.wjgnet.com/bpg/gerinfo/204)

### GUIDELINES FOR ETHICS DOCUMENTS


### GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

[https://www.wjgnet.com/bpg/gerinfo/240](https://www.wjgnet.com/bpg/gerinfo/240)

### PUBLICATION ETHICS


### PUBLICATION MISCONDUCT

[https://www.wjgnet.com/bpg/gerinfo/208](https://www.wjgnet.com/bpg/gerinfo/208)

### ARTICLE PROCESSING CHARGE


### STEPS FOR SUBMITTING MANUSCRIPTS

[https://www.wjgnet.com/bpg/gerinfo/239](https://www.wjgnet.com/bpg/gerinfo/239)

### ONLINE SUBMISSION

[https://www.ffpublishing.com](https://www.ffpublishing.com)

### PUBLISHING PARTNER’S OFFICIAL WEBSITE

[https://www.shca.org.cn](https://www.shca.org.cn)
[https://www.zs-hospital.sh.cn](https://www.zs-hospital.sh.cn)
Basic Study

Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma

Yi-Ying Wang, Mei-Mei Shen, Jian Gao

**Abstract**

**BACKGROUND**

Metadherin (MTDH) is a key oncogene in most cancer types, including hepatocellular carcinoma (HCC). Notably, MTDH does not affect the stemness phenotype or immune infiltration of HCC.

**AIM**

To explore the role of MTDH on stemness and immune infiltration in HCC.

**METHODS**

MTDH expression in HCC tissues was detected using TCGA and GEO databases. Immunohistochemistry was used to analyze the tissue samples. MTDH was stably knocked down or overexpressed by lentiviral transfection in the two HCC cell lines. The invasion and migration abilities of HCC cells were evaluated using Matrigel invasion and wound healing assays. Next, we obtained liver cancer stem cells from the spheroids by culturing them in a serum-free medium. Gene expression was determined by western blotting and quantitative reverse transcription PCR. Flow cytometry, immunofluorescence, and tumor sphere formation assays were used to characterize stem-like cells. The effects of MTDH inhibition on tumor growth were evaluated in vivo. The correlation of MTDH with immune cells, immunomodulators, and chemokines was analyzed using ssGSEA and TISIDB databases.

**RESULTS**

HCC tissues expressed higher levels of MTDH than normal liver tissues. High MTDH expression was associated with a poor prognosis. HCC cells overexpressing MTDH exhibited stronger invasion and migration abilities, exhibited a stem cell-like phenotype, and formed spheres; however, MTDH inhibition...
attenuated these effects. MTDH inhibition suppressed HCC progression and CD133 expression in vivo. MTDH was positively correlated with immature dendritic, T helper 2 cells, central memory CD8+ T, memory B, activated dendritic, natural killer (NK) T, NK, activated CD4+ T, and central memory CD4+ T cells. MTDH was negatively correlated with activated CD8+ T cells, eosinophils, activated B cells, monocytes, macrophages, and mast cells. A positive correlation was observed between the MTDH level and CXCL2 expression, whereas a negative correlation was observed between the MTDH level and CX3CL1 and CXCL12 expression.

CONCLUSION

High levels of MTDH expression in patients with HCC are associated with poor prognosis, promoting tumor stemness, immune infiltration, and HCC progression.

Key Words: Metadherin; Hepatocellular carcinoma; Cancer stem cells; Immune infiltration

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

INTRODUCTION

Primary liver cancer is one of the six most common cancers and the third leading cause of cancer-related deaths worldwide. About 75%-85% of primary liver cancer cases are caused by hepatocellular carcinoma (HCC)[1]. The treatment of liver tumors, is limited by its complex pathogenesis, postoperative recurrence, and drug resistance[2]. The poor prognosis of patients with this disease is attributable to metastasis and high recurrence rates. Therefore, it is crucial to understand the relevant mechanisms underlying HCC and identify new therapeutic approaches and targets.

According to several studies, a small proportion of tumor cells, including those in HCC and colorectal cancer, are capable of self-renewal, proliferation, and differentiation, and they are referred to as cancer stem cells (CSCs)[3,4]. The surface markers of CSCs in HCC include CD133, CD90, and EpCAM. High expression levels of CSC markers of CSCs increase stem cell characteristics and tumor sphere-forming capacity[5-7]. An infiltration of multiple immune cells occurs in HCC, including T lymphocytes[8], B cells[9], dendritic cells (DCs)[10], and natural killer (NK) cells[11]. The HCC consists of these tumor-infiltrating immune cells. The type and number of immune cells have prognostic value and can influence the response to immunotherapy.

Metadherin (MTDH), also known as astrocyte elevated gene-1 or lysine-rich CEACAM1, is a key oncogenic gene in most cancer types[12]. In malignant tumors, MTDH promotes proliferation capacity[13], migration[14], cell survival, and angiogenesis[15], as well as poor prognosis, in lung, prostate, and breast cancers. The importance of MTDH in HCC has been demonstrated in numerous studies[16,17]; however, the effects of the expression of MTDH on stem cell characteristics and immune cell infiltration in HCC remain unclear.

Compared with normal liver tissues, liver cancer tissues showed higher levels of MTDH expression. Notably, MTDH expression was associated with poor prognosis. Our findings showed that MTDH was expressed at higher levels in tumor spheres than in adherent cells. MTDH expression in HCC cells positively correlated with CD133, Oct4, and Nanog expression in stem cells. Furthermore, the inhibition of MTDH expression inhibited tumor growth. Our study confirmed that MTDH is associated with immune cell infiltration, as confirmed by the analysis of the ssGSEA and TISIDB databases.

MATERIALS AND METHODS

HCC Samples

All the gene expression profile files and the clinical information were obtained from two public databases. TCGA (The Cancer Genome Atlas database, https://portal.gdc.cancer.gov/) contains information on transcriptional gene expression in human cancer and healthy tissues. After removing samples with incomplete clinical information, 369 liver tumor tissues and 50 healthy liver tissues were analyzed. In the GEO (Gene Expression Omnibus, www.ncbi.nlm.nih.gov/geo/), incompletely annotated samples were excluded from the dataset of GSE14520 (sequencing platform: GPL3921). The
analysis included 210 samples, comprising both tumor samples and their corresponding non-cancer pairs. The clinical information of all the samples is presented in Table 1. Liver tumor tissue microarrays of nine paired samples (HLiv-H030PG03) were purchased from Shanghai Xinchao (Shanghai, China).

**Differential expression and survival analyses**

TCGA data were converted to TPM (transcripts per million) values for subsequent analyses. For GSE14520, data normalization and log2 transformation were performed. Probe IDs were converted to gene symbols using a platform annotation file. Genes with multiple probes are represented by their maximum expression values. Data pre-processing was performed, followed by differential expression and statistical analyses using R software. A survival curve analysis was performed using the R packages “Survival” and “Survminer” with the best cut-off value for MTDH calculated for both datasets. R packages “ggstatsplot” and “corrplot” were used for data visualization.

**Cell culture**

Huh7 cells were purchased from the Chinese Academy of Sciences Cell Bank and, MHCC-97H cells were obtained from the Liver Cancer Institute at Fudan University Zhongshan Hospital. All the cells were cultured in DMEM medium [10% fetal bovine serum (FBS)], 100 U/mL penicillin, and 100 U/mL streptomycin in an incubator with 5% CO₂.

**Sphere formation assay**

Tumor spheres were cultured in serum-free medium (SFM) consisting of 20 ng/mL EGF (PeproTech), DMEM/F12 (HyClone), 20 ng/mL bFGF (PeproTech), and 20 μL/mL B27 (Gibco). Single cells (1 × 10⁴) were seeded in a 6-well ultra-low adsorption plate (Corning) containing 1.5 mL of serum-free culture medium. All the cells were incubated for 14 days in incubators with 5% CO₂ at 37°C. Inverted microscopes were used to count tumor spheres larger than 50 mm.

**Extraction of proteins and western blotting**

To prepare proteins from the cells, the cells were lysed in RIPA solution (CWBIO) containing a protease inhibitor cocktail solution. The protein concentration in the solution was determined using a BCA kit (Beyotime). Proteins were separated by using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (Beyotime Millipore) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). PVDF membranes were closed with 5% skim milk at room temperature (RT) for 1 h, followed by overnight incubation with primary antibody at 4°C. The membranes were washed thrice with TBST containing 0.1% Tween-20, followed by incubation with secondary antibodies (EuroClone) (1:5000) for 1 h. After washing with TBST, for 5 min, the blots were visualized with chemiluminescence reagents (Beyotime). The antibodies used were anti-MTDH (CST, 14065T), anti-CD133 (YT5192, ImmunoWay), anti-NANOG (CST, 4903T), and anti-GAPDH (YM3215, ImmunoWay).

**Total RNA extraction and real-time quantitative reverse transcription PCR**

TRIzol (Takara) was used to extract RNA from the cells, and the cDNA (complementary DNA) composition was determined using the PrimeScript™ RT Reagent Kit (TaKaRa). Real-time quantitative reverse transcription PCR (qRT-PCR) was performed using SYBR Premix Ex Taq (TaKaRa). A CFX96 Real-Time PCR Detection System (Bio-Rad) was used for qRT-PCR analysis. PCR was performed using the primers purchased from Sangon Biotechnology (Shanghai, China). The 2⁻ΔΔCt method was used to calculate the data. Table 2 shows primer sequences.

**Cell transfection**

To establish a cell line with stable overexpression and suppression of MTDH, the cell were infected with a lentivirus. MTDH-overexpressing lentiviral vectors, MTDH-RNAi lentiviral vectors, and blank control lentiviral vectors were acquired from GeneChem (Shanghai, China). On the previous day, 3 × 10⁴ cells were grown in each well of a six-well plate. When the cells reached 30% confluence, they were transfected according to the manufacturer’s protocols at Multiplicity of Infection of 5. After 96 h, fluorescence microscopy and western blotting were used to verify the transfection efficiency. Puromycin screening was then performed for 2 wk (GeneChem).

**Immunofluorescence**

The cells were seeded in a 24-well plate. Paraformaldehyde solution (4%) was used to fix the cells for 20 min after 24 h of incubation. For cell membrane permeabilization, the cells were treated with 0.3% Triton-X-100 (Sigma) for 15 min. The cells were incubated overnight with anti-NANOG antibody at 4°C after 120 min incubation in 5% BSA in TBST. Next, the cells were washed with PBS and incubated with DyLight 649 AffiniPure Goat Anti-Rat IgG (1:200, Abbkine) for 1 h in a dark humidified box. The final counterstaining was done using DAPI (4',6-diamino-2-phenylindole) for 10 min. Images were captured using a fluorescence microscope (Nikon).

**Wound healing assay**

MHCC-97H and Huh7 cells were cultured in six-well plates. Subsequent experiments were performed when the cell density in the wells reached 90%. After scratching the cells with a 200-μL pipette, 2% FBS cell culture medium was used for continued culture. All the cells were incubated with 5% carbon dioxide in an incubator at 37°C. A microscope was used to photograph the wounded areas.
Table 1 Description of the datasets used in this study

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>GSE14520</th>
<th>TCGA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total (n = 210)</td>
<td>%</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 60</td>
<td>169</td>
<td>80.48</td>
</tr>
<tr>
<td>≥ 60</td>
<td>41</td>
<td>19.52</td>
</tr>
<tr>
<td>Unknown</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>26</td>
<td>12.38</td>
</tr>
<tr>
<td>Male</td>
<td>184</td>
<td>87.62</td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>T2</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>T3</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>T4</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Unknown</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>N1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Nx</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Unknown</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>M stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>M1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mx</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>90</td>
<td>42.86</td>
</tr>
<tr>
<td>II</td>
<td>75</td>
<td>35.71</td>
</tr>
<tr>
<td>III</td>
<td>43</td>
<td>20.48</td>
</tr>
<tr>
<td>IV</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Unknown</td>
<td>2</td>
<td>0.95</td>
</tr>
<tr>
<td>Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alive</td>
<td>130</td>
<td>61.90</td>
</tr>
<tr>
<td>Dead</td>
<td>80</td>
<td>38.10</td>
</tr>
<tr>
<td>Unknown</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>HBV status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVR-CC</td>
<td>52</td>
<td>24.76</td>
</tr>
<tr>
<td>CC</td>
<td>152</td>
<td>72.38</td>
</tr>
<tr>
<td>Unknown</td>
<td>6</td>
<td>2.86</td>
</tr>
</tbody>
</table>

HBV: Hepatitis B virus; AVR: Active viral replication chronic carrier; CC: Chronic carrier.
Invasion and migration assays
The migration and invasion abilities of the cells were assessed using 24-well transwell chambers with or without Matrigel (BD Biosciences). The supplements were kept in 5% CO₂ at 37°C for 12 h. Next, 2 × 10⁵ cells were re-suspended in 200 µL of SFM and placed in transwell cups with an 8-micron pore membrane (BD). Simultaneously, cell culture medium containing 10% FBS was added to the lower layer to make a total volume of 600 µL. The chambers were maintained in 5% CO₂ for 24 h at 37°C. The cells that failed to pass through the pores and remained in the upper chamber were carefully wiped off with a cotton swab. Migrating cells were fixed in 4% paraformaldehyde solution for 20 min. Next, the cells remaining in the chambers were stained in 200 µL 0.1% crystal violet for 30 min, followed by counting with a microscope in five random areas.

Flow cytometry
The cells were washed with PBS after trypsin digestion. Next, they were suspended in 80 µL of PBS, followed by the addition of 2 µL PE-CD133 antibody (Miltenyi Biotec) and 20 µL of FcR Blocking Reagent (Miltenyi Biotec). Under light-proof conditions, the mixture was incubated at 4°C for 10 min. Next, all the cells were washed thrice in PBS, followed by resuspension with 500 µL of PBS. The mixture was analyzed using a FACS Calibur Flow cytometer (BD Biosciences).

Animal experiments
BALB/c-nu mice were obtained from the Animal Experiment Center of Chongqing Medical University. The experiments were conducted in the animal facilities of the Animal Experiment Center of Chongqing Medical University (12-h light/dark cycle, 27 ± 2°C, 50% ± 10% humidity). Nude mice were randomly divided into two groups of three mice each. MHCC-MTDH-LV cells (2 × 10⁶ cells) were re-suspended in a complete culture medium. Next, 100 µL of cell suspension were subcutaneously injected into nude mouse (female, 4-6 wk old). The tumors were detached after 4 wk. Next, the tumor volume was calculated using the following formula: Length × width²/2. Tumor tissues were subjected to immunohistochemical staining (IHC) analysis. This study was approved by the Ethics Committee of the Second Hospital of Chongqing Medical University.

IHC
All the slides were dewaxed and gradually hydrated. Antigen extraction was performed using citrate buffer under high pressure and temperature conditions. All the slides were rinsed with PBS and incubated with goat serum for 10 min at RT. Next, the slides were exposed to anti-MTDH and anti-CD133 at 4°C overnight. Subsequently, horseradish peroxidase-labeled streptavidin was added, followed by the addition of DAB reagent. Tap water was dehydrated using an ethanol gradient. The slides were then washed twice with xylene and wrapped in neutral balsam. Protein expression levels were assessed using the ImageJ software. The average optical density was calculated by measuring the integrated optical density and the area of each image, which reflected the concentration per unit area of the target protein.

ssGSEA
The infiltration abundances of 28 immune cell species in TCGA samples were quantified using ssGSEA. The gene set data for the immune cells were downloaded from the website (https://www.cell.com/cms/10.1016/j.celrep.2016.12.019/). Box plots were constructed to compare immune cell differences between the groups. The R package used was “GSVA” [18]. “ggplot2.”

TISIDB database
TISIDB is an online analysis site for the analysis of tumor-immune interactions (http://cis.hku.hk/TISIDB/)[19]. To further investigate the immunological impact of MTDH in cancer, we analyzed and evaluated the TISIDB database through the "Immunomodulators" and “chemokine modules”.

Statistical analysis
All the experiments were conducted at least thrice. Data were analyzed using R 4.1.2 and GraphPad Prism software. Student’s t-test was used to compare two groups of continuous variables. The Kruskal-Wallis and Wilcoxon tests were used for non-parametric tests. A P value < 0.05 indicated statistical significance.

RESULTS

MTDH is upregulated in HCC and positively associated with poor prognosis
To identify aberrant MTDH expression in HCC, we downloaded microarray gene profiling data from GEO (GSE14520/GPL3921) and TCGA. In 50 normal liver tissues and 369 Liver cancer tissues from TCGA, MTDH mRNA expression was upregulated in liver tumor tissues. Similarly, MTDH expression was increased in the tumor in GSE14520 (n = 420; Figure 1A and B). MTDH expression was examined in human HCC (n = 9) and paracancerous tissues (n = 9) using IHC. According to these results, HCC tissues overexpressed MTDH, compared with the para-cancerous tissues (Figure 1C). Furthermore, we constructed the Kaplan-Meier curve of HCC using “Survival” and “Survminer” R packages. Shorter survival times were associated with higher MTDH (Figure 1D and E). A higher expression of MTDH was observed in liver cancer tissues than in normal liver tissues or para-cancerous tissues, which had impact on the prognosis of patients with liver cancer.
Table 2 Primers used in this study

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metadherin</td>
<td>5′-CCAGGCTCCTTCATCAACTT-3′</td>
<td>5′-AthAAGCAGCCACCAGAGATTG-3′</td>
</tr>
<tr>
<td>CD133</td>
<td>5′-TGATGCGACGTCCGTACAAGT-3′</td>
<td>5′-ATACCTGTACGACAGTGCTGAGT-3′</td>
</tr>
<tr>
<td>Nanog</td>
<td>5′-AAAGGTGACCTTGACCGAGATG-3′</td>
<td>5′-TGGTCACACCATGTGATCTGCT-3′</td>
</tr>
<tr>
<td>Oct4</td>
<td>5′-CAGAGGCTGATTGCTGATGAT-3′</td>
<td>5′-GAAGGCTGGGCTACTT-3′</td>
</tr>
<tr>
<td>GAPDH</td>
<td>5′-CAGGAGGCATTGCTGATGAT-3′</td>
<td>5′-GAAGGCTGGGCTACTT-3′</td>
</tr>
</tbody>
</table>

**Figure 1** Metadherin overexpression has been linked to a worse prognosis in hepatocellular carcinoma. A and B: Metadherin (MTDH) mRNA expression in normal liver tissues compared with liver cancer tissues; C: Images of para-carcinoma (n = 9) and cancer tissues (n = 9) stained with MTDH by Immunohistochemical staining (scale bar = 200 μm); D and E: Patient’s overall survival curves according to MTDH expression. \( P < 0.0001, \) \( P < 0.01. \) Normal: Normal liver tissues; Cancer: Liver cancer tissues; Para-carcinoma: Para-cancerous tissue; MTDH: Metadherin; IHC: Immunohistochemical staining.

**MTDH promotes HCC cell migration and invasion**

Two cell lines, Huh7 and MHCC-97H, were transfected with the related lentiviruses. Specifically, we used a blank control (LV-NC) vs overexpression (LV-OE) and a blank control (LV-NC) vs knockdown (LV-RNAi), to obtain stable overexpression and suppression of MTDH. Western blotting was performed to verify MTDH protein expression after transfection (Figure 2A). The migration and invasion assays showed that MTDH overexpression significantly accelerated the migration and invasion of MHCC-97H and Huh7 cells (Figure 2B). Conversely, MTDH knockdown cells exhibited lower potential for migration and invasion (Figure 2C). The wound healing assay confirmed that MTDH overexpression significantly promoted wound healing, whereas MTDH knockdown suppressed scratch wound healing in HCC cells (Figure 2D). These results indicate that high MTDH expression correlates positively with the migration and invasive abilities of HCC cells.

**MTDH is associated with the CSCs phenotypes in HCC**

To determine whether MTDH is related to the stem cell phenotype, we examined MTDH and HCC stemness using TCGA database. TCGA data showed a significant positive correlation between MTDH expression in HCC tissues and CD133, NANOG, and Oct4 expression (n = 369; Figure 3A). Our previous research confirmed that liver CSCs (LCSCs) can be enriched using a serum-free stem cell medium to promote tumor sphere formation. Next, we performed SFM on MHCC-97H and Huh7 cells, followed by western blotting and qRT-PCR to determine MTDH expression in stem cell spheres and attached cells. Compared with liver cancer-adherent cells, LCSCs expressed increased mRNA levels of MTDH and the stem cell markers (CD133, Oct4, and Nanog; Figure 3B). The results showed that the protein expression levels of MTDH, CD133, and NANOG were higher than those in liver cancer adherent cells (Figure 3C). These results showed that MTDH was highly expressed in LCSCs.
Figure 2 Metadherin promotes proliferation, migration, and invasion of hepatocellular carcinoma cells. A: In Huh7 and MHCC-97H cells, Western blotting revealed the efficacy of Metadherin overexpression and knockdown; B and C: Characteristic images of trans-well invasion assays 24 h after culture; D: Images depicting scratch width at 0 h and 48 h post-scratch in cells captured using inverted microscopy. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. OE: Metadherin overexpression group; NC: Overexpression control group; RNAi: Metadherin knockdown group; RNAi-NC: MTDH knockdown control group.

Overexpression of MTDH enhances the LCSCs phenotypes

To confirm that MTDH maintained stem-like phenotypes in HCC cells, stem cell markers were detected in MHCC-97H and Huh7 cell lines overexpressing MTDH (CD133, Oct4, Nanog). Through PCR experiments, we demonstrated that the markers of CSCs markers were higher in MTDH-overexpressing cells than in the NC groups (Figure 4A). MTDH-overexpressing Huh7 and MHCC-97H cells also expressed high levels of CD133 and Nanog protein (Figure 4B). A sphere culture assay showed the formation of more spheres in MTDH-overexpressing Huh7 and MHCC-97H cells than in control cells (Figure 4C). Flow cytometry revealed that MTDH overexpression effectively increased the number of CD133+ HCC cells (Figure 4D). In addition, MTDH overexpression effectively enhanced CSCs phenotypes in HCC cells.

MTDH knockdown inhibits LCSCs phenotypes

The PCR results demonstrated that the mRNA expression of stem cell markers in MTDH-RNAi cells was lower than that in the NC group (Figure 5A). In contrast to the NC group, MTDH-RNAi cells showed lower expression of CD133 and...
Figure 3 Metadherin correlates with the stemness properties in hepatocellular carcinoma. A: Correlation between Metadherin (MTDH) and CD133, Nanog, Oct4 in TCGA; B: Through quantitative reverse transcription PCR, the expression levels of MTDH, CD133, Nanog, Oct4 were measured in attached cells and tumor spheres in 97H and Huh7 cell lines. In tumor spheres, all the four genes were expressed at increased levels; C: MTDH, CD133, and Nanog were higher in attached cells than in tumor spheres. Gene GAPDH served as the internal reference. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. CSC: Cancer stem cells; CC: Cancer cells.

Nanog (Figure 5B). The downregulation of MTDH reduced the numbers of both MHCC-97H and Huh7 cell spheres, compared with those in the control LV-NC group, as indicated by the results of the sphere culture assay (Figure 5C). The results of the immunofluorescence showed that Nanog fluorescence intensity was greater in the NC group than in the MTDH-RNAi group (Figure 5D). Taken together, these results confirm that the inhibition of MTDH expression attenuates the acquisition of the HCC stem cell phenotype.

MTDH knockdown reduces tumor growth and CD133 expression in vivo

Male BALB/c nude mice were injected with LV-NC or LV-MTDH-RNAi MHCC-97H cells to evaluate the effect of MTDH on tumor growth. The MTDH-RNAi group exhibited a smaller tumor volume than the 97H-NC group, confirming that MTDH promotes tumor growth (Figure 6A and B). Images of hematoxylin and eosin-stained tumor tissues of nude mice are shown in Figure 6C. To further clarify the role of MTDH in the tumor stem cell phenotype, CD133 and MTDH proteins were detected by IHC in the tumor tissues of nude mice. We found that CD133 expression decreased with reduced MTDH expression (Figure 6D). Therefore, these results further suggest that MTDH overexpression promotes liver tumor growth and the CSCs phenotype.

MTDH expression and immune cell infiltration

A significant association was observed between immune cell infiltration and survival in patients with HCC. Using ssGSEA, we quantified immune cell infiltration scores in HCC samples from TCGA to understand the relationship
Figure 4 Metadherin overexpression promotes stem cell phenotypes and self-renewal in hepatocellular carcinoma cell lines. A and B: Through quantitative reverse transcription PCR polymerase chain reaction and Western blot, we determined Metadherin expression and stemness markers; C: The typical pictures of sphere formation assays from 97H-overexpression and Huh7-overexpression cells; D: Flow cytometric analysis of CD133⁺ cells in 97H-overexpressing and Huh7-overexpressing cells. *P < 0.05, **P < 0.01. OE: Metadherin overexpression group; NC: Overexpression control group; MTDH: Metadherin.

between MTDH and infiltration. Firstly, the results demonstrated a significantly higher infiltration of activated B cell, immune B, memory B, activated CD8 T, gamma delta T, effector memory CD8 T, central memory CD8 T, and effector memory CD4 T cells in healthy tissue than in HCC. Similarly, higher infiltration of eosinophils, immature DCs, myeloid-derived suppressor cells, monocytes, macrophages, mast cells, monocytes, neutrophils, NK cells, NK T cells, and T helper (Th) cells were observed in healthy tissue than in HCC (Figure 7A). These findings suggest that immune cells are essential in the progression of HCC. Based on the median MTDH expression, we divided the liver cancer samples in TCGA into high and low MTDH expression groups and assessed immune cell infiltration in both groups. Notably, the levels of memory B (P < 0.0001), immature dendritic (P < 0.001), Th2 (P < 0.001), and central memory CD4⁺ T (P < 0.01) cells were higher in the high MTDH expression group than that in the low group. In the low MTDH expression group, activated CD8 T cells (P < 0.0001), macrophages (P < 0.01), activated B cells (P < 0.01), effector memory CD8 T cells (P < 0.01), mast cells (P < 0.01), eosinophils (P < 0.05), monocytes (P < 0.05), and Th1 cells (P < 0.05) were significantly increased.
Figure 5 Metadherin downregulation inhibits hepatocellular carcinoma stem cell phenotypes. A: mRNA expression of Metadherin (MTDH), CD133, Nanog, and Oct4 in 97H and Huh7-RNAi; B: In comparison with that of MTDH-LV-RNAi, the protein expression of CD133 and Nanog was elevated in MHCC-97H-NC and Huh7-NC cells; C: Images depicting sphere formation by 97H-RNAi and Huh7-RNAi cells; D: Immunofluorescence images of Nanog (red) in 97H-LV and Huh7-LV samples. DAPI (blue) was used to stain the nuclei. *P < 0.05, **P < 0.01, ***P < 0.001. RNAi: Metadherin knockdown group; RNAi-NC: Metadherin knockdown control group.

We examined the relationship between immune cells and MTDH expression (Figure 8A). Immature dendritic (r = 0.28, P < 0.0001; Figure 8B), Th2 (r = 0.26, P < 0.0001; Figure 8C), memory B (r = 0.25, P < 0.0001; Figure 8D), central memory CD4 T (r = 0.22, P < 0.0001; Figure 8E), central memory CD8 T, NK T, activated dendritic, activated CD4 T, and NK cells also showed a positive relationship with MTDH. Activated CD8 T cells (r = -0.23, P < 0.0001; Figure 8F), eosinophils (r = -0.13, P < 0.05; Figure 8G), activated B cells (r = -0.12, P < 0.05; Figure 8H), monocytes (r = -0.12, P < 0.05; Figure 8I), macrophages, and mast cells showed a negative correlation with MTDH.

Correlation of MTDH expression with immunomodulators and chemokines
ICIs (immune checkpoint inhibitors) are gaining increasing attention as tumor immunotherapy strategies for different types of cancers, facilitating improved prognosis in some patients. MTDH and the various immunosuppressive agents in the TISIDB database did not show significant correlation, as indicated by our online analysis (Figure 9A). However, in the analysis of correlation with immunostimulants (Figure 9B), a positive correlation was found between MTDH and MICB (r = 0.207, P = 5.76 × 10^-5; Figure 9C), NTSE (r = 0.201, P = 9.8 × 10^-5; Figure 9D), and TNFSF14 (r = 0.143, P = 0.00576; Figure 9E). Based on these results, MTDH may be involved in the regulation of tumor immunity.

Chemokines and their receptors induce cell migration. The expression of MTDH correlated with that of chemokines and receptors in immune cells, based on the data from the TISIDB database (Figure 10A and B). In HCC, MTDH expression positively correlated with CXCL2 (r = 0.224, P = 1.34 × 10^-5; Figure 10C) and negatively correlated with CX3CL1 (r = 0.245, P = 1.73 × 10^-5; Figure 10D) and CXCL12 (r = 0.208, P = 5.4 × 10^-5; Figure 10E). However, MTDH expression was not significantly correlated with chemokine receptor expression.
Figure 6 Metadherin stimulates tumorigenesis in vivo. A: Tumors derived from nude mice injected with 97H-RNAi (n = 3), 97H-NC cell (n = 3); B: Tumor volume showed that the inhibition of Metadherin (MTDH) significantly inhibited tumor growth; C and D: Representative immunohistochemical staining (IHC) images of tumors from nude mice stained with CD133 and MTDH. Histograms show the IHC score. Histograms show the IHC score (scale bars = 200 μm). *P < 0.01, **P < 0.001, ***P < 0.0001. RNAi: Metadherin knockdown group; RNAi-NC: Metadherin knockdown control group.

DISCUSSION

This study demonstrated that MTDH expression was higher in HCC tissues than in normal liver tissues and was associated with shorter survival time, stronger migration, and invasive ability. This study also focused on the effects of MTDH on stemness acquisition and immune infiltration of HCC cells. MTDH promotes stemness in HCC cells and high MTDH expression may impede the effectiveness of cancer immunotherapy. The findings of this study will provide additional information that can enhance the understanding of the prognosis and treatment of HCC patients.

It has been reported that the expression level of MTDH correlates with serum alpha-fetoprotein level[20], microvascular infiltration, tumor differentiation, and TNM stage[21]. In addition, the 1-year, 3-year and 5-year overall survival (OS) rates of the high-expression group were significantly lower than those of the low-expression group, and the cumulative recurrence rate was significantly higher than that of the low-expression group[21]. Univariate and multivariate analyses identified AEG-1 as an independent prognostic factor for OS and recurrence[22]. The findings of Yoo et al[22] showed that MTDH expression gradually increased in phases I-IV and from high differentiation to low differentiation. Differential expression, immunohistochemistry, and survival analysis showed similar results. The findings indicate that MTDH is closely associated with poor clinical prognosis of HCC. Additional studies have revealed that MTDH participates in proliferation, tumor progression, invasiveness[23], and metastasis[13]. We performed invasion, migration, and scratch assays on HCC cell lines with overexpressed and under-expressed MTDH. The results suggest that MTDH plays a role in HCC progression, which is consistent with the report of Yoo et al[22].

CSCs are capable of promoting metastasis and enhancing resistance to tumor therapies, including liver cancer therapy[24]. CD133, NANOG, Oct4, and several other molecular markers related to stemness maintenance in human CSCs have been reported[25,26]. Notably, CD133 is a surface marker for LCSCs. The co-expression of Nanog and OCT4 is associated with aggressive tumor behavior and worse clinical outcomes in HCC cells. A study by Hu et al.[27] found strong correlations among MTDH, CD133, and SOX2 Levels in gliomas. However, the contribution of MTDH to the tumor stem cell phenotype in HCC remains unclear. We explored the correlation between MTDH and stem cell markers in HCC using correlation analysis and experimental studies. The three stemness markers in the TCGA LIHC dataset exhibited positive correlation with MTDH expression. Additionally, MTDH expression increased in HCC spheres. The overexpression of MTDH in HCC cells enhanced their self-renewal ability, increased the proportion of CD133+ cells, and promoted the expression of tumor stemness markers. However, after MTDH knockdown, stem cell markers were less expressed, and self-renewal was suppressed. The tumorigenic experiments were performed using nude mice. The primary tumor size was reduced in the MTDH-suppressed group, with decreased CD133 protein expression. These results confirm that MTDH plays a regulatory role in HCC stem cells. Therefore, in this study, we demonstrated that MTDH promoted an increase in tumor stem cells in HCC cells, which could lead to a worse prognosis.
MTDH can influence the Wnt/β-catenin, Ha-ras, and PI3K/Akt pathways. The Wnt/β-catenin pathway maintains the CSCs phenotype [28]. In gastric cancer, MTDH forms a complex with β-Catenin and LEF1, facilitating the promotion of β-catenin protein translocation and activation of genes downstream of Wnt signaling [29]. CD133 glioma cells overexpressing MTDH maintain stemness and drug resistance through Wnt/β-catenin protein signaling [27]. The precise mechanism through which MTDH regulates CSCs in HCC should be further elucidated in the future.

MTDH increases the expression of PD-L1 and up-regulates the transcriptional activity of PD-L1 through the β-catenin/lev-1 signaling pathway. Patients with HCC and high MTDH and PD-L1 expression may benefit more from PD-1 monoclonal therapy. This suggests that MTDH is associated with immunity against HCC [30]. Immunotherapy resistance in tumor cells is related to components outside the tumor cells in the tumor microenvironment. Mature DCs can induce specific immune responses in the body, acting as anti-infection and anti-tumor agents. Conversely, immature DCs can inhibit the function of antigen-specific effector T cells in the body to further induce immune tolerance. There are different...
Figure 8 Immune infiltration and Metadherin expression levels. A: Metadherin (MTDH) expression levels correlated with infiltration of immune cells; B:
Correlations between MTDH and immature dendritic cells ($r = 0.28, P < 0.0001$); C: Correlations between MTDH and T helper 2 cells ($r = 0.26, P < 0.0001$); D: Correlations between MTDH and memory B cells ($r = 0.25, P < 0.0001$); E: Correlations between MTDH and central memory CD4 T cells ($r = 0.22, P < 0.0001$); F: Correlations between MTDH and activated CD8 T cell ($r = -0.23, P < 0.0001$); G: Correlations between MTDH and eosinophils ($r = -0.13, P < 0.05$); H: Correlations between MTDH and activated B cells ($r = -0.12, P < 0.05$); I: Correlations between MTDH and monocytes ($r = -0.12, P < 0.05$). MTDH: Metadherin.

Figure 9 Correlation between Metadherin expression and immunomodulators. A and B: Heat map showing the correlation between Metadherin (MTDH) and immunosuppressive agents and immunostimulants in hepatocellular carcinoma; C: Correlations between MTDH and MICB; D: Correlations between MTDH and NT5E; E: Correlations between MTDH and TNFSF14. MTDH: Metadherin.

subpopulations of CD4+ Th cells, which include Th1, Th2, and Th17 cells. It has been shown that Th2 cytokines (IL-4 and IL-10) promote tumor growth and metastasis, while Th1 cytokines (IL-2 and TNF-α) are associated with a good prognosis in HCC\cite{31,32}. We found that a high level of MTDH expression positively correlated with an increase in Th2 cells and immature DCs. We speculated that MTDH may increase immune tolerance and metastasis of tumor cells by regulating the infiltration level of immature DC or Th2 cells, which in turn leads to poor prognosis in patients. In contrast, MTDH exhibited negative correlation with the infiltration levels of activated CD8+ T cells, eosinophils, activated B cells, and monocytes. These findings suggest that MTDH plays a critical role in regulating tumor immune infiltration in HCC.

MTDH significantly correlated with the immunostimulants (MICB, NT5E, and TNFSF14). Chemokines initiate lymphocyte infiltration early in the development of malignancies to enhance the activities of antitumor agents. Chemokines reduce apoptosis, promote proliferation, enrich CSCs in tumors, and increase the resistance of tumor cells to therapy\cite{33}. Analyzing the TISIB database revealed a positive correlation between MTDH and CXCL2 expression levels and a negative correlation between MTDH, CXCL12, and CX3CL1 expression levels. CXCL2 promotes the invasion and migration of HCC cells\cite{34}. The recurrence rate of intrahepatic or extrahepatic metastases is lower in patients with HCC expressing high levels of CX3CL1 and its receptor, CX3CR1\cite{35}. HPMEC (human lung microvascular endothelial cells) exhibit an MTDH-mediated attraction towards suspension-cultured cells through the CXCR4/CXCL12 axis, suggesting that MTDH promotes HCC cell metastasis through the CXCR4/CXCL12 pathway\cite{36}. Our analysis showed that MTDH expression negatively correlated with CCXCL12 and CXCR4, but not significantly with CXCR4. This finding was
inconsistent with our anticipated results. Exploring the interactions and the associated mechanisms between CCXCL12 and MTDH will further elucidate the role of MTDH in HCC.

This study had some limitations. The exact mechanism through which MTDH influences HCC stem cells needs further investigation both in vivo and in vitro. Additionally, although we found that MTDH expression was closely associated with immune infiltration and prognosis, a more in-depth investigation is essential to elucidate the exact mechanism of MTDH-mediated immune infiltration.

**CONCLUSION**

High MTDH expression is associated with poor prognosis in HCC. MTDH may influence HCC progression through the regulation of tumor stemness and immune infiltration, providing additional evidence for the possible role of MTDH as a potential molecular marker of HCC.

**ARTICLE HIGHLIGHTS**

**Research background**

Metadherin (MTDH) is a key oncogene in most cancer types, including hepatocellular carcinoma (HCC). Tumor stem cells are associated with tumorigenesis, metastasis, cell proliferation, and postoperative recurrence. The type and number

---

**Figure 10** Chemokines and chemokine receptor correlates with Metadherin. A and B: A correlation analysis of Metadherin (MTDH) and chemokines and the receptors in LIHC is presented as a heat map; C: Correlations between MTDH and CXCL2; D: Correlations between MTDH and CX3CL1; E: Correlations between MTDH and CXCL12. MTDH: Metadherin.
of immune cells in the HCC microenvironment have prognostic value and can influence the response to immunotherapy. The impacts of MTDH expression on stem cell characteristics and immune cell infiltration in HCC remain unclear.

**Research motivation**
MTDH is a key oncogene in most cancers. It is important to explore the impact of MTDH on the prognosis of HCC patients and determine whether it affects tumor progression by influencing stem cell phenotype and immune infiltration.

**Research objectives**
This study aimed to investigate the effects of MTDH on tumor stemness and immunity in HCC.

**Research methods**
Differential expression of MTDH in tissues was detected using TCGA and GEO databases, and immunohistochemistry was performed on HCC and para-cancerous tissue samples. MTDH was stably downregulated or overexpressed by lentiviral transfection in both HCC cell types. Invasiveness and migration were assessed using stromal infiltration and wound healing assays. HCC stem cells were obtained by culturing spheroids in a serum-free medium. Flow cytometry, immunofluorescence, and sphere formation assays were used to identify stem-like cells. Relevant gene expression was detected through western blotting and real-time quantitative reverse transcription-PCR. The effect of MTDH inhibition on tumor growth was investigated using in vivo tumor formation assays. Correlations between MTDH and immune cells, immunomodulators, and chemokines were analyzed using ssGSEA and the TISIDB database.

**Research results**
This study confirmed that the expression of MTDH in HCC tissues was higher than that in normal liver tissues and that the high expression of MTDH resulted in poor prognosis of patients with HCC. HCC cells overexpressing MTDH exhibited stronger invasion and migration abilities, exhibited a stem cell-like phenotype, and formed spheres, whereas MTDH inhibition attenuated these effects. MTDH inhibition suppressed tumor growth and CD133 expression in vivo. Correlation analysis showed that MTDH exhibited positive correlation with immature dendritic cells (DCs), T helper (Th)2 cells, central memory CD8+ T cells, memory B cells, activated DCs, natural killer (NK) T cells, NK cells, activated CD4+ T cells, and central memory CD4+ T cells. The results also showed that MTDH exhibited negative correlation with activated CD8+ T cells, eosinophils, activated B cells, monocytes, macrophages, and mast cells. Correlation analysis of MTDH expression with immunomodulators and chemokines showed that MTDH levels positively correlated with CXCL2 expression and negatively correlated with CX3CL1 and CXCL12 expression.

**Research conclusions**
In HCC, MTDH expression is increased, leading to poor prognosis. MTDH promotes the acquisition of tumor cell stemness and tumor growth in HCC, influencing immune infiltration and immunotherapy.

**Research perspectives**
Through database analysis, as well as in vivo and in vitro experiments, we confirmed that MTDH leads to poor prognosis in patients with HCC, promotes the acquisition of the tumor stem cell phenotype, and influences immune infiltration. The exact mechanism through which MTDH influences HCC stem cell and immune cell infiltration requires further exploration. This may provide a scientific basis for further understanding of the prognosis and treatment of patients with HCC.

**ACKNOWLEDGEMENTS**
We would like to thank Institute of Life Sciences, Chongqing Medical University for technical support.

**FOOTNOTES**

**Author contributions:** Wang YY and Shen MM performed the experiments and wrote the manuscript; Gao J revised the manuscript; all the authors have approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 82173359; Basic Research and Frontier Exploration Project of Chongqing and Technology Commission, No. cstc2018jcyjAX0181; and Kuanren Talents Program of The Second Affiliated Hospital of Chongqing Medical University.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by The Ethics Committee of the Second Hospital of Chongqing Medical University [Protocol No. 2023(4)].

**Conflict-of-interest statement:** No conflict of interest has been declared by any of the authors.

**Data sharing statement:** No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.

Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Yi-Ying Wang 0000-0001-7550-4826; Jian Gao 0000-0002-9799-160X.

S-Editor: Lin C
L-Editor: A
P-Editor: Chen YX

REFERENCES


17. **Jin C**, Han-Hua D, Qiu-Meng L, Deng N, Peng-Chen D, Jie M, Lei X, Xue-Wu Z, Hui-Fang L, Yan C, Xiao-Ping C, Bi-Xiang Z. MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular
Carcinoma. Oncogene 2023; 42: 169-183 [PMID: 36385375 DOI: 10.1038/s41388-022-02545-x]


